FRANKLIN LAKES, N.J.,
Sept. 22, 2016 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, today announced it is investing
$100 million in its Holdrege, Neb. facility to expand capacity for
its insulin syringe manufacturing operations.
The investment will be used for new technology and manufacturing
equipment to expand capacity for BD insulin syringes. BD already
produces more than 2 billion insulin syringes each year, which
averages to be more than 250,000 syringes per hour.
"About 40 percent of people with diabetes who inject insulin use
syringes as part of their diabetes management regimen," said
Ken Miller, worldwide president of
Diabetes Care for BD. "This investment will provide benefits to
this diabetes population and underscores our commitment to supply
high-quality, industry-leading insulin syringes to patients."
BD began operations in Holdrege
in 1966 in a 12,000 square foot building with 66 associates. Today,
the facility has grown to 350,000 square feet with more than 650
associates manufacturing 20 different BD products. BD is the
largest employer in Phelps County.
Across Nebraska, BD employs more
than 2,500 associates in four manufacturing facilities in
Holdrege, Broken Bow and two in Columbus.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, optimize
respiratory care and support the management of diabetes. The
company partners with organizations around the world to address
some of the most challenging global health issues. BD has more than
45,000 associates across 50 countries who work in close
collaboration with customers and partners to help enhance outcomes,
lower health care delivery costs, increase efficiencies, improve
health care safety and expand access to health. For more
information on BD, please visit bd.com.
Contacts:
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-invests-100-million-in-nebraska-plant-to-expand-insulin-syringe-manufacturing-300332348.html
SOURCE BD (Becton, Dickinson and Company)